6 completed, 1 active not recruiting, 1 terminated. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Dysgerminoma: new trials by email Literature Review of Dysgerminoma trials Research Report on Dysgerminoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disorders of Sexual Development and Gonadal Tumor Risk Not applicable . Non-interventional retrospective study, only on datas. - Disorders of Sexual Development | Completed | Hospices Civils de Lyon | 80 | 2023-09-01 | 2025-04-13 | |
| Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Durvalumab, Tremelimumab - Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2017-05-15 | 2026-09-18 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Cognitive Assessment, Quality-of-Life Assessment - Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor | Completed | Gynecologic Oncology Group | 247 | 2010-04-01 | 2018-04-12 | |
| Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment sunitinib malate - Extragonadal Germ Cell Tumor, Ovarian Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 10 | 2007-03-01 | 2015-10-27 |
| Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors pegfilgrastim, cisplatin, ifosfamide - Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 60 | 2007-03-01 | 2017-11-28 |
| Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors lapatinib, paclitaxel - Bladder Cancer, Brain and Central Nervous System Tumors | Phase 1 | Completed | University of California, San Francisco | 28 | 2006-02-01 | 2014-07-02 |
| Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP) Darbepoetin alfa - Dysgerminoma | Phase 2 | Completed | University Hospital Tuebingen | 108 | 2003-07-01 | 2009-02-16 |
| Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer imatinib mesylate, therapeutic conventional surgery, laboratory biomarker analysis - Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor | Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2002-06-01 | 2013-01-17 |
Ovarian Neoplasms (4) · Seminoma (4) · Testicular Neoplasms (3) · Carcinoma, Embryonal (2) · Central Nervous System Neoplasms (2) · Endodermal Sinus Tumor (2) · Teratoma (2) · Testicular Germ Cell Tumor (2) · Androgen-Insensitivity Syndrome (1) · Anorchia (1) · Breast Neoplasms (1) · Brenner Tumor (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1)
Neoplasms by Histologic Type (8) · Germinoma (7) · Neoplasms (7) · Neoplasms, Germ Cell and Embryonal (7) · Endocrine System Diseases (6) · Gonadal Disorders (6) · Urogenital Diseases (6) · Endocrine Gland Neoplasms (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Male Urogenital Diseases (5) · Neoplasms by Site (5) · Urogenital Neoplasms (5) · Adnexal Diseases (4)
Paclitaxel (2) · Albumin-Bound Paclitaxel (1) · Cisplatin (1) · Darbepoetin alfa (1) · Ifosfamide (1) · Imatinib Mesylate (1) · Lapatinib (1) · Mental Status and Dementia Tests (1) · Sunitinib (1) · Taxes (1) · durvalumab (1) · pegfilgrastim (1) · tremelimumab (1)
Memorial Sloan Kettering Cancer Center (3) · Gynecologic Oncology Group (1) · Hospices Civils de Lyon (1) · National Cancer Institute (NCI) (1) · University Hospital Tuebingen (1) · University of California, San Francisco (1)
United States (6) · France (1) · Germany (1)
Robert J. Motzer, MD (2) · Christopher Ryan (1) · Darren Feldman, MD (1) · Dean F. Bajorin, MD (1) · Joerg T. Hartmann, MD (1) · Lisa Hess (1) · Mark M. Moasser, MD (1) · Samuel Funt, MD (1)
P30CA008748 (1), U10CA031946 (1), U10CA101165 (1)